Children

Genotropin^® is a GH therapy indicated for GHD¹

The dosage and administration schedule should be individualised. The injection should be given subcutaneously and the site varied to prevent lipoatrophy.

Growth disturbance due to insufficient secretion of GH in children

Generally, a dose of 0.025 to 0.035 mg/kg body weight per day (0.7-1.0 mg/m² body surface area per day) is recommended. Even higher doses have been used. Where childhood-onset GHD persists into adolescence, treatment should be continued to achieve full somatic development
(e.g. body composition and bone mass). For monitoring, the attainment of a normal peak bone mass defined as a T score >−1 (i.e. standardised to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period.

PWS for the improvement of growth and body composition in children

Growth disturbance due to TS

A dose of 0.045 to 0.050 mg/kg body weight per day (1.4 mg/m² body surface area per day) is recommended.

Growth disturbance in short children born SGA

A dose of 0.035 mg/kg body weight per day (1 mg/m² body surface area per day) is usually recommended until the final height is reached (see Section 5.1). Treatment should be discontinued after the first year of treatment if the height velocity SDS is below +1. Treatment should be discontinued if the height velocity is <2 cm/year and, if confirmation is required, bone age is >14 years (girls) or >16 years (boys), corresponding to the closure of the epiphyseal growth plates.

Dosage Recommendations in Pediatric Patients

Adapted from Genotropin. Local product document. 2022. LPDSOM052020.

GH, growth hormone; GHD, growth hormone deficiency; PWS, Prader-Willi syndrome; SDS, standard deviation score; SGA, small for gestational age; TS, Turner syndrome.

Reference: